If you’d like to advertise a position here please email our Communications Officer at email@example.com
If you’re looking to be the next potential pioneer in phagetherapy, consider applying for a Ph.D. with Karen Weynberg (University of Queensland) & Paul Jaschke (Macquarie University) to work on synthetic biology tools to fight UTI bacteria
Title: Treatment of multi-drug resistant infections using a novel, rapid, and customised synthetic phage therapy platform.
Description: Antimicrobial resistance is increasing at an alarming rate globally. Therefore, there is an urgent need to develop alternative, and potentially complementary, therapeutics to combat pathogenic microbes. The use of phage therapeutic methods in a variety of environments is poorly explored. This project aims to explore further the use of phage therapy by establishing an innovative synthetic biology platform to engineer phage therapy candidates within a biofoundry and will leverage the candidate’s skills in one or more of the following areas – microbiology, molecular biology, genetic engineering and laboratory automation. This project will focus on treating multi-drug resistant uropathogenic E. coli (UPEC), which is responsible for one of the most common illnesses – urinary tract infection – and is increasingly associated with antibiotic resistance. Successful outcomes of this project will be peer-reviewed publications in high-impact journals, intellectual property, and the chance to make a positive difference in the lives of people chronically infected by UPEC pathogens.
Preferred requirements: First class Honours/ Masters in a related discipline such as Microbiology, Molecular Biology, Bioengineering, or Virology
*The successful candidate must commence by Research Quarter 2, 2021. You should apply at least 3 months prior to the research quarter commencement date. International applicants may need to apply much earlier for visa reasons.
Synthetic Biology Postdoctoral Research Associate (University of Florida – Horticultural Sciences Dept)
A synthetic biology postdoctoral position is open in Andrew Hanson’s group at University of Florida https://www.adhansonlab.org/
The Hanson Group is applying synthetic biology approaches to engineering plant and microbial metabolism. Their research aims for a utility to agriculture and the bioeconomy.
Ongoing projects include:
– Using directed evolution via the E. coli EvolvR system (PMID:30069054) and the yeast OrthoRep system (PMID:30415839) to build more energy-efficient versions of the thiamin synthesis enzyme THI4 (PMID:30337452)
– Using directed evolution to extend the working lives of enzymes, and so cut the high energy cost of replacing them (PMID: 30670486)
– Developing new-to-nature synthetic metabolic pathways that benefit agriculture and the environment
We collaborate extensively (via joint Federally-funded projects) and publish with groups at UF, in other US institutions, and in Europe. These groups include synthetic biologists, metabolic engineers, computational biochemists, and plant biochemists.
For our publications see https://scholar.google.com/citations?user=NMKoQqEAAAAJ&hl=en&oi=ao
The position involves contributing to lab management, e.g. by overseeing ordering or coordinating the performance of everyday tasks by other lab members.
– Ph.D. degree in biochemistry, microbiology, chemistry, biotechnology, or a related discipline
– Proven organizational, time-management, and communication skills (oral and written)
– Experience with E. coli and preferably also yeast as genetic and metabolic platform organisms
– Strong interest in applying synthetic biology to metabolic engineering
– Strong interest in plants and plant improvement
Starting salary: $47,476/year. Fringe benefits include health insurance.
To Apply: Please send a letter of application, a detailed CV, and names and email addresses of three referees to firstname.lastname@example.org
Postdoctoral Associate in Chemical and Synthetic Biology
School of Chemistry, The University of Sydney
13 April 2020
generous employer’s contribution to superannuation
Dr Yu Heng Lau, groups.chem.usyd.edu.au/lau/